Kairos Pharma, Ltd. (KAPA)

Market Cap	27.80M
Revenue (ttm)	n/a
Net Income (ttm)	-4.71M
Shares Out	20.74M
EPS (ttm)	-0.33
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,637,604
Open	1.310
Previous Close	1.680
Day's Range	1.210 - 1.470
52-Week Range	0.400 - 3.250
Beta	n/a
Analysts	Strong Buy
Price Target	8.33 (+521.64%)
Earnings Date	Nov 13, 2025

About KAPA

Kairos Pharma, Ltd., a clinical-stage biopharmaceutical company, develops therapeutics for cancer patients. Its therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. The company develops KROS 101, an orally available glucocorticoid-induced tumor necrosis factor receptor (GITR) ligand small-molecule antagonist to deplete regulatory T cells (Tregs) and activate effector T cells to augment the antitumor immune response for the treatment of patients with cancer, and a...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Sep 16, 2024
• Employees: 4
• Stock Exchange: NYSEAMERICAN
• Ticker Symbol: KAPA
• Website: https://kairospharma.com

Analyst Summary

According to 3 analysts, the average rating for KAPA stock is "Strong Buy." The 12-month stock price target is $8.33, which is an increase of 521.64% from the latest price.

Price Target

$8.33

(521.64% upside)

Analyst Consensus: Strong Buy